



**REVISION TO THE SUMMON OF
ANNUAL GENERAL MEETING OF SHAREHOLDERS FOR FISCAL YEAR 2024
PT KIMIA FARMA TBK**

Referring to the Summon of the Annual General Meeting of Shareholders of PT Kimia Farma Tbk (the “**Company**”) for Fiscal Year 2024, which was published on the Indonesia Stock Exchange website (www.idx.co.id), eASY.KSEI via <https://easy.ksei.co.id> and the Company’s official website www.kimiafarma.co.id on July 7, 2025, the Company hereby inform its shareholders that the AGMS of PT Kimia Farma Tbk for Fiscal Year 2024 (the “**MEETING**”), previously scheduled for July 29, 2025, has been rescheduled to:

Day and Date : **Wednesday, July 30, 2025**
Time : **16.00 WIB until completion**
Link to Join : Access the Electronic General Meeting System KSEI (eASY.KSEI) through the AGMS the link <https://akses.ksei.co.id> provided by KSEI.

In accordance with Regulations No. 15/POJK.04/2020 and No. 16/POJK.04/2020 concerning the electronic conduct of **MEETING**, the Notary, relevant Professionals, and Supporting Institutions will coordinate the electronic implementation of the MEETING at Indonesia Health Learning Institute, located at Jl. Cipinang Cimpedak I No. 36, East Jakarta.

With **MEETING** Agendas as follows:

1. **Board of Directors’ report on the Delay of the Annual General Meeting of Shareholders for the Fiscal Year 2024.**
2. **Approval of the Company's Annual Report and Ratification of the Company's Consolidated Financial Statements of the Fiscal Year 2024, Approval of the Board of Commissioners Oversight Report of the Fiscal Year 2024, including Ratification of the Re-issue and Restatement of the Financial Statements of the Fiscal Year 2023, and Ratification of the Implementation Report of the Micro and Small Business Funding Programme of the Fiscal Year 2024, as well as Granting full release and discharge (*volledig acquit et de charge*) to the Board of Directors for the Company's Management Actions and the Board of Commissioners for the Company's Supervisory Actions that have been carried out during the Fiscal Year 2024 and for the Re-issue and Restatement of the Consolidated Financial Statements for the Fiscal Year 2023.**
3. **Approval of the Allocation of the Company's Net Profit for the Fiscal Year 2024.**
4. **Determination of Salary/Honorarium along with Facilities and Allowances for Fiscal Year 2025, as well as Tantiem/Performance Incentives/Special Incentives for the Performance of Fiscal Year 2024 for the Board of Directors and Board of Commissioners of the Company.**

5. **Approval of the Appointment of a Public Accountant and/or Public Accounting Firm (KAP) to audit the Company's Financial Statements for Fiscal Year 2025 as well as the Financial Statements of the Micro and Small Business Funding Program (PUMK) for Fiscal Year 2025.**
6. **Report on the Implementation of the Mandatory Convertible Bonds (OWK) Conversion into Shares for the Purpose of Increasing the Company's Capital, and Approval to Grant Authority to the Company's Board of Commissioners to Determine the Amount of Issued and Paid-up Capital Increase.**
7. **Change in the Composition of the Company's Management.**

The date of the Shareholders Register (Recording Date), which contains the list of the Company's shareholders entitled to attend the **MEETING**, as well as all provisions and procedures previously announced in the prior Summon, remain valid and unchanged.

In accordance with the Financial Services Authority Regulation Number 15/POJK.04/2020 concerning the Planning and Organization of General Meetings of Shareholders of Public Companies and the provisions of the Company's Articles of Association, this revision to the Summon of the **MEETING** is announced through the Indonesia Stock Exchange website, eASY.KSEI via <https://akses.ksei.co.id>, and the Company's website.

This, this Revision to the Summon of the **MEETING** is hereby conveyed for the attention and understanding of the Company's shareholders.

Jakarta, July 8, 2025
The Board of Directors
PT Kimia Farma Tbk